Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance. Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalCurrent Gastroenterology Reports
Volume10
Issue number3
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Pediatrics
Maintenance
Therapeutics
Infliximab
Safety

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{32a94fcd880c46d99a5689b7cd6a737c,
title = "Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease",
abstract = "Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance. Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.",
author = "Joel Rosh",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s11894-008-0060-5",
language = "English (US)",
volume = "10",
pages = "302--307",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "3",

}

Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. / Rosh, Joel.

In: Current Gastroenterology Reports, Vol. 10, No. 3, 01.12.2008, p. 302-307.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease

AU - Rosh, Joel

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance. Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.

AB - Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance. Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.

UR - http://www.scopus.com/inward/record.url?scp=54049115991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049115991&partnerID=8YFLogxK

U2 - 10.1007/s11894-008-0060-5

DO - 10.1007/s11894-008-0060-5

M3 - Review article

C2 - 18625142

AN - SCOPUS:54049115991

VL - 10

SP - 302

EP - 307

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 3

ER -